Prothrombin complex concentrates: Difference between revisions
| Line 25: | Line 25: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*DIC | *[[DIC]] | ||
*known HIT (Heparin induced thrombocytopenia) | *known [[HIT]] (Heparin induced thrombocytopenia) | ||
===Serious=== | ===Serious=== | ||
| Line 33: | Line 33: | ||
===Common=== | ===Common=== | ||
*thromboembolic events (8.7%) | *thromboembolic events (8.7%) | ||
*headache (7.8%) | *[[headache]] (7.8%) | ||
*hypotension (4.9%) | *[[hypotension]] (4.9%) | ||
*nausea/vomiting | *[[nausea/vomiting]] | ||
*arthralgia | *arthralgia | ||
*ICH (2.9%) | *[[ICH]] (2.9%) | ||
*mental status change (2.9%) | *mental status change (2.9%) | ||
*hypertension (2.9%) | *hypertension (2.9%) | ||
Revision as of 17:58, 28 May 2015
General
- Type: Hemostatics, blood components
- Dosage Forms:lypophilized concentrate for reconstitution 500u/vial and 1000u/vial
- Common Trade Names: Kcentra
Adult Dosing
- Based on pretreatment INR, units based on factor 9 content
- INR 2-4: 25units/kg, not to exceed 2500 units
- INR 4-6: 35units/kg, not to exceed 3500 units
- INR >6: 50units/kg, not to exceed 5000 units
Pediatric Dosing
Safety and efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation: Unknown, breast feeding not advised
- Renal Dosing
- Adult-N/A
- Pediatric-N/A
- Hepatic Dosing
- Adult-N/A
- Pediatric-N/A
Contraindications
Serious
- thromboembolism
- blood product (hepatitis, HIV)
Common
- thromboembolic events (8.7%)
- headache (7.8%)
- hypotension (4.9%)
- nausea/vomiting
- arthralgia
- ICH (2.9%)
- mental status change (2.9%)
- hypertension (2.9%)
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
See Also
Sources
Medscape